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Soluble Amyloid-beta Aggregates
from Human Alzheimer’s Disease
Brains
Thomas J. Esparza1, Norelle C. Wildburger1, Hao Jiang1, Mihika Gangolli2, Nigel J. Cairns1,3,4,
Randall J. Bateman1,3,4 & David L. Brody1,2,4
Soluble amyloid-beta (Aβ) aggregates likely contribute substantially to the dementia that characterizes
Alzheimer’s disease. However, despite intensive study of in vitro preparations and animal models, little
is known about the characteristics of soluble Aβ aggregates in the human Alzheimer’s disease brain.
Here we present a new method for extracting soluble Aβ aggregates from human brains, separating
them from insoluble aggregates and Aβ monomers using differential ultracentrifugation, and purifying
them >6000 fold by dual antibody immunoprecipitation. The method resulted in <40% loss of starting
material, no detectible ex vivo aggregation of monomeric Aβ, and no apparent ex vivo alterations in
soluble aggregate sizes. By immunoelectron microscopy, soluble Aβ aggregates typically appear as
clusters of 10–20 nanometer diameter ovoid structures with 2-3 amino-terminal Aβ antibody binding
sites, distinct from previously characterized structures. This approach may facilitate investigation
into the characteristics of native soluble Aβ aggregates, and deepen our understanding of Alzheimer’s
dementia.
Clinically defined dementia of the Alzheimer’s type (DAT) is the most common cause of age-related progressive
cognitive dysfunction. Post-mortem, pathologically defined Alzheimer’s disease (AD) is present in the majority of patients diagnosed during life with DAT. The ‘Amyloid Cascade Hypothesis’, a leading idea regarding the
cause of DAT, is derived from genetic studies of both age-related and familial early onset disease, both of which
implicate increased production and aggregation of the Aβ peptide1,2. Thus, Aβhas been the major target for
disease-modifying therapeutic development. However, the extent of Aβdeposition correlates only modestly with
dementia; many middle aged and elderly people have extensive plaque deposition without any signs of dementia3–7. Furthermore, Aβdeposition begins decades before the onset of dementia8.
In recent years, water-soluble Aβaggregates (varyingly termed Aβoligomers, amyloid derived diffusible ligands, Aβ*56, amylospheroids, annular protofibrils, and other appellations) have been implicated more directly
in causing synaptic dysfunction and neuronal cell death in vitro9–16 as well as impaired behavioral performance
in animal models17–19. Soluble Aβaggregates have been detected in human brain lysates from AD patients15,20–35.
However, these aggregates are highly heterogeneous15,23,24,26–28,32,35–39, and it is unclear whether the characteristics
of the soluble Aβaggregates in the human brain are similar to the soluble Aβaggregates in animal models or in
vitro preparations37. Of note, native human brain soluble Aβaggregates are orders of magnitude more toxic than
similar size synthetic aggregates24,27. Furthermore, determining the relationship between human patients and animal models is of vital importance because to date, Aβ-targeted therapeutics developed using these animal models
have not been successful at reversing DAT or altering disease progression.
Our group reported development of a sensitive, specific, quantitative, and high-throughput assay for soluble
Aβ aggregates40 (termed ‘oligomers’ in that publication). The assay uses the monoclonal antibody HJ3.4 which
is specific for the canonical N-terminus of Aβ40; it does not recognize amyloid precursor protein, unlike other
commonly used antibodies such as 6E10 or 4G8. Using this assay, we were able to fully distinguish between DAT
patients and high pathology non-demented controls with no overlap between groups based on the ratio of soluble
Aβaggregates to plaque area40.
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Figure 1. Method for isolating and purifying soluble Aβ aggregates from human AD brain. Cortical tissue
was dounce homogenized in sub-critical micelle concentration of the detergent CHAPS, size forms of Aβ were
isolated by differential ultracentrifugation, then Aβwas purified by dual antibody immunoprecipitation and
elution in ammonium hydroxide. RCF: relative centrifugal force. Sol.: soluble, LMW: low molecular weight,
HMW: high molecular weight. IP: immunoprecipitation.
However, a major challenge has been that the specific forms of soluble Aβaggregates most relevant to human
disease have not been determined. Aβcan potentially aggregate into a vast number of forms, consisting of different numbers of Aβpeptides, various size forms of Aβ, multiple Aβpost-translational modifications and alternative structural configurations of Aβ. It has not been clear which of these aggregation forms are most relevant
to AD. Here we report a method to purify soluble Aβaggregates directly from frozen human AD brain tissue,
reasoning this would be the most relevant source for the species directly underlying dementia in humans.

Results

Our approach to isolating soluble Aβaggregates from human brain involved tissue homogenization, differential
ultracentrifugation, and dual antibody immunoprecipitation (Fig. 1). During the methods development phase,
we broke the problem down into three tasks: 1) Maximizing extraction of soluble Aβaggregates from human
Alzheimer’s disease brain tissue; 2) Isolating the soluble Aβaggregates from other forms of Aβ; 3) Separating the
soluble Aβaggregates from other proteins.
We tested multiple different methods to address each of these tasks, and used four criteria to quantitatively
assess the overall results: 1) Quantitative completeness of separation of the soluble Aβaggregates from soluble
monomers and insoluble aggregates; 2) Fold enrichment of Aβcompared to total protein; 3) Quantitative completeness of the recovery of the soluble Aβaggregates present in the starting material, i.e. minimization of loss
during purification; and 4) Minimization of ex vivo aggregation or disaggregation of Aβduring the extraction
and purification process.
For quantification of soluble Aβaggregates at each step of the process, we used a 96 well plate-based assay
(Supplementary Fig. 1A) modified from our previously reported 384 well plate assay40. The soluble Aβ aggregate
assay uses the same antibody, HJ3.4, to capture and detect Aβ. Monomeric Aβis captured but not detected due to
epitope masking by the capture antibody. For quantitation, the assay uses synthetic Aβdimers, so the quantitative
units are ‘dimer equivalents’ even though the assay measures soluble aggregates of many sizes. This assay has a
lower limit of quantitative reliability of 31.25 pg/mL dimer equivalents and an approximately 100-fold dynamic
range. It is relatively high throughput, such that a single investigator can run up to 6 plates per day. However it
only recognizes aggregates with ≥2 free canonical N-termini and thus should be considered an assay for just this
class of soluble Aβaggregates. At each step of the process, we also quantified total Aβwith a free N-terminus
(Aβ1−x) using a different 96 well plate-based ELISA with HJ5.1, a mid-domain Aβantibody, as the capture antibody and HJ3.4 as the detection antibody (Supplementary Fig. 1B).

Extraction of soluble Aβ aggregates.

We tested a variety of single extraction, serial extraction and
detergent-enhanced extraction methods. We determined that a single extraction by dounce homogenization
in phosphate buffered saline (PBS) plus a sub-critical micelle concentration (0.45% weight/volume) of the
zwitterionic detergent [(3-Cholamidopropyl)dimethylammonio]-1-Propanesulfonate (CHAPS) was appropriate. PBS + 0.45% CHAPS extraction yielded nearly 2-fold higher concentrations of soluble Aβ aggregates
than extraction in PBS alone, and more than PBS + 4 other detergents at sub-critical micelle concentrations
(Supplementary Fig. 2A). Furthermore, while a second extraction in PBS alone yielded 36% additional soluble
Aβaggregates after the first extraction, a second extraction in PBS+0.45% CHAPS yielded only 15% additional
soluble Aβaggregates and subsequent extractions yielded very little additional soluble Aβaggregate, indicating
efficient first pass extraction in PBS + 0.45% CHAPS (Supplementary Fig. 2B–D). Notably, even after 5 extractions in PBS + 0.45% CHAPS, additional Aβcould be extracted in 0.5 M Guanidine (Supplementary Fig. 2C).
Taken together, these results were consistent with the material in the first PBS + 0.45% CHAPS extraction representing efficient extraction of a finite pool of soluble Aβaggregates but not consistent with extraction of normally
insoluble Aβfrom plaques.
Importantly, extraction in PBS + 0.45% CHAPS did not result in ex vivo aggregation of monomeric Aβ.
We isolated native monomeric Aβfrom human Alzheimer’s disease (CDR3) brain tissue (Fig. 1), then added
the AD-derived monomer (2 ng/mL) to the buffer during the homogenization of cognitively normal, AD
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Figure 2. Sub-critical micelle concentration of CHAPS in PBS does not induce ex vivo aggregation of
human AD brain derived Aβ monomers. (A) Titration of CHAPS during homogenization of normal control
cortical tissue spiked with 2 ng/mL human AD brain-derived Aβmonomer. No induction of detectible Aβ
aggregates. (B–D). Size exclusion chromatography of the 475,000× g RCF sucrose cushion fraction from
normal control cortical tissue spiked with 2 ng/mL AD brain-derived Aβmonomer. (B) Total protein, (C)
Soluble Aβaggregate assay indicating no detectible Aβaggregates, (D) Aβ1−x assay indicating <10% of spiked
monomer present in sucrose cushion (high molecular weight enriched) portion of the preparation. LoQ: limit
of quantitation.

pathology-negative human brain tissue in the presence of sub-critical micelle concentrations of CHAPS. The
homogenates were centrifuged at 100,000× g prior to assessment using the dimer equivalent ELISA. We observed
no ELISA signal at each concentration, indicating that 0.45% CHAPS did not induce ex vivo formation of soluble Aβaggregates within the level of detection (Fig. 2A). Furthermore, there were no soluble Aβ aggregates
detected after 475,000× g RCF ultracentrifugation (Fig. 2B–D). We repeated this control experiment using synthetic Aβ1-42 and found no effect of 0.45% CHAPS on soluble Aβaggregate formation as a function of concentration of synthetic Aβ1-42 up to 20 ng/mL (Supplementary Fig. 3). In contrast, the commonly used detergent
sodium dodecyl sulfate (SDS) dramatically enhanced ex vivo aggregation of Aβat concentrations of 0.2% or
higher (Supplementary Fig. 4), which may be relevant for interpretation of results from other groups that used
this detergent in the context of polyacrylamide gel electrophoresis (see Supplementary Discussion). Triton X-100
also caused some ex vivo aggregation at 1%, but Tween-20 did not affect aggregation at concentrations up to 1%
(Supplementary Fig. 4). In summary, we found that a single extraction in PBS + 0.45% CHAPS provided a high
yield of soluble Aβaggregates from human brain tissue without causing detectible ex vivo aggregation, but other
detergents such as SDS and Triton X-100 appeared to cause ex vivo aggregation.

Minimizing non-specific loss of Aβ.

It became clear during our investigations of soluble Aβ aggregate
extractions that the quantities of these aggregates were not stable over time; there was a rapid loss of Aβ aggregates, likely due to nonspecific binding to surfaces. Even low-protein binding tubes and tips did not eliminate
this loss. We therefore modified our technique to include blocking of every tube and every pipet tip with a 1%
bovine serum albumin (BSA) solution. With BSA blocking, non-specific loss was dramatically reduced both at
room temperature and 4 °C (Supplementary Fig. 5). BSA blocking reduced loss of Aβbut had no apparent effect
on the size exclusion chromatography profile of Aβin human brain lysates (Supplementary Fig. 6). Without albumin blocking, we estimate that >90% of all Aβaggregates would have been lost during even our most efficient
purification protocols.

Isolation of soluble Aβ aggregates from other forms of Aβ. For the second task, separating soluble
Aβaggregates from other forms of Aβ, we used a differential ultracentrifugation protocol. By definition, solubilizing the preparation in PBS separates ‘soluble’ forms of Aβfrom ‘insoluble’ forms of Aβ. We pelleted the less
soluble forms of Aβby centrifugation at 100,000× g (Fig. 1). Subsequent experiments demonstrated that the
forms of Aβin the 100,000× g pellet were morphologically distinct from the more soluble forms of Aβpresent in
the 100,000× g supernatant (see Fig. 6, below).
Previously40, we demonstrated using size exclusion chromatography that the soluble Aβaggregates extracted
from human brain detected by our assay were large, eluting close to the void volume in fractions 7–10 near
the 670 kDa globular protein size standard on a Superdex 200 column (Fig. 3A–C). In contrast, monomeric Aβ
is ~4 kDa in size, eluting in fractions 19–21. We therefore considered using size exclusion chromatography to
separate soluble Aβaggregates from monomers, but found that this method was inefficient for scale-up because
size exclusion chromatography performed poorly for large liquid volumes. We lysed each gram of brain in 10 mL
of buffer whereas only 1 mL at a time could be run on size exclusion chromatography. We next considered the
use of molecular weight cutoff centrifuge filters, but found that there was substantial loss of soluble Aβ aggregates during this process and that it did not efficiently remove low molecular weight species from the retentate
(Supplementary Fig. 7). Third, we considered ammonium sulfate precipitation of high molecular weight aggregates. This method scaled up well, did not result in substantial loss of soluble Aβaggregates, and did not induce
ex vivo aggregation of monomeric Aβ, but it did not fully separate soluble Aβaggregates from endogenous monomeric Aβ(Supplementary Fig. 8). Finally, we turned to differential ultracentrifugation and found that 1 hour at
475,000× g kept monomeric Aβin the upper phase and pelleted the soluble Aβaggregates. Because the soluble
Scientific Reports | 6:38187 | DOI: 10.1038/srep38187
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Figure 3. Enrichment and preservation of soluble high molecular weight Aβ aggregates from human AD
brain following differential centrifugation and immunoprecipitation. (A) Size exclusion chromatography
(SEC) total protein profile (measured by absorption) of a CDR3 tissue homogenate prepared in 1xPBS
containing 0.45% CHAPS; overlay with Bio-Rad gel filtration standards (red) with molecular weight in kDa
indicated (red text). (B,C). Soluble Aβaggregate and Aβ1−x assays on SEC fractions of original lysates. LoQ:
limit of quantitation. (D) SEC total protein profile of the sucrose cushion fraction after ultracentrifugation at
475,000×  g. (E,F) Soluble Aβaggregate and Aβ1−x assays on SEC fractions of sucrose cushion fraction after
ultracentrifugation at 475,000× g, demonstrating the preservation of soluble Aβaggregates and separation
from monomers. (G) SEC total protein profile (measured by NanoOrange) of the 475,000× g sucrose cushion
fraction followed by immunoprecipitation (IP), washing, and elution with ammonium hydroxide. (H,I) Soluble
Aβaggregate and Aβ1−x assays on eluted high molecular weight soluble Aβ aggregates. Insets: Quantification of
protein (note log scale in panel G), soluble Aβaggregates, and Aβ1−x in the immunoprecipitation bead washes.
Aβaggregates were difficult to completely resuspend after pelleting at 475,000× g, we modified the 475,000×  g
ultracentrifugation protocol to include a 70% sucrose cushion, allowing nearly complete recovery of the soluble
Aβaggregates. The Aβin the 475,000× g sucrose cushion was essentially all high molecular weight with nearly
undetectable low molecular weight Aβ(Fig. 3D–F). In a complementary fashion, the Aβin the 475,000×  g supernatant fraction was entirely low molecular weight (Fig. 4). This method could be applied to up to 8 tubes at a time
with 26 mL of material per tube. These results confirmed that differential ultracentrifugation was an effective and
scalable method to separate soluble Aβaggregates from other forms of Aβ.

Separation of soluble Aβ aggregates from other proteins.

For the third task, separating soluble
Aβaggregates from other proteins, we considered immunoprecipitation, ion exchange chromatography, and
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Figure 4. Aβ monomer is the predominant size form of Aβ from human AD brain in the top layer after
475,000× g ultracentrifugation. (A) SEC total protein profile from 1 mL of the top 5 mL supernatant layer
removed following ultracentrifugation at 475,000×  g. (B) Aβ1−x assay on the same supernatant SEC fractions.

Figure 5. “Quantitative bookkeeping”. Total protein and soluble Aβaggregate assays (note log scale)
performed on each step of the isolation and purification of soluble Aβaggregates from human AD brain.
hydrophobicity chromatography; we settled on a dual antibody immunoprecipitation with ammonium hydroxide elution as the final method.
Ion exchange chromatography with strong anion and strong cation exchangers at neutral and basic pH’s were
tested (acidic pH’s were avoided to prevent passing Aβthrough its pKa at ~5.5). Anion exchange chromatography
at pH 8 yielded a discrete soluble Aβaggregate peak (Supplementary Fig. 9A,B) but only a 3.1 fold enrichment
of soluble Aβaggregates compared with total protein. The peak occurred over 14 mL, resulting in substantial
dilution.
Hydrophobicity interaction chromatography with several resins (butyl sepharose, phenyl sepharose, and octyl
sepharose) and several mobile phases (sodium chloride, ammonium sulfate, sodium sulfate) was tested. No clear
enrichment of soluble Aβaggregates was obtained, and the soluble Aβaggregates eluted over a broad range of salt
concentrations (Supplementary Fig. 9C,D).
Scientific Reports | 6:38187 | DOI: 10.1038/srep38187
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Figure 6. Immunoelectron microscopic analysis of soluble Aβ aggregates from human AD brain in
comparison to low molecular weight Aβ and insoluble aggregates. Labeling was performed using the
anti-Aβantibody HJ3.4 followed by anti-mouse secondary conjugated to 6 nm diameter gold beads. (A) Exemplar
immunoelectron microscopic images of low molecular weight (LMW) Aβimmunoprecipitated from the 475,000×  g
supernatant. White arrows indicate individually resolved objects with typically 1 but occasionally 2 gold beads. Scale
bar = 100 nm. Inset shows a single 6 nm gold bead, with scale bar 10 nm. (B) Exemplar immunoelectron microscopic
images of soluble high molecular weight (HMW) Aβaggregates immunoprecipitated from the sucrose cushion
after 475,000× g ultracentrifugation. Arrows indicate compact aggregates with multiple gold beads. (C) Exemplar
immunoelectron microscopic images of insoluble high molecular weight Aβaggregates immunoprecipitated from
the pellet after 100,000× g ultracentrifugation. Arrows indicate elongated and irregular aggregates with multiple
gold beads per aggregate. (D) Surface area measurements (in nm2, note log scale) of the gold labeled objects in the
three fractions: LMW (blue circles), soluble HMW (orange squares), and insoluble (red triangles). Preparations were
made from 6 AD patients; 10 random fields per patient were analyzed in an automated fashion. (E). Number of gold
particles per aggregate were counted in an automated fashion from the same images.
Immunoprecipitation using beads conjugated with two different monoclonal antibodies recognizing two distinct epitopes was used to increase avidity. We used HJ3.4 recognizing the canonical free AβN-terminus, and
HJ5.1 recognizing a mid-domain epitope conjugated directly to cyanogen bromide sepharose beads. Incubation
of brain lysates overnight at 4 °C with these dual antibody conjugated beads resulted in a complete immunodepletion of Aβ; no detectible Aβwas present in the supernatant. Elution in the detergent lithium docecyl sulfate
(LDS) at 95 °C dramatically altered the size forms of Aβ, elution in the high salt buffer 5 M lithium chloride
resulted in incomplete recovery, and elution in acidic conditions with 200 mM glycine pH 2.7 resulted in almost
no recovery (Supplementary Fig. 10A–C). In contrast, elution in 150 mM ammonium hydroxide pH 10.5 resulted
in nearly complete recovery of Aβwithout changing the size forms resolved on size exclusion chromatography
(Supplementary Fig. 10D). Immunoprecipitation of the isolated high molecular weight soluble Aβ aggregates
from the 475,000× g sucrose cushion with these dual antibody beads and elution with ammonium hydroxide
resulted in a nearly complete recovery of Aβ, a sharpening of the Aβpeak into fractions 8–9, and no change in
the size forms of Aβpresent (Fig. 3G–I). Total protein fell ~1000 fold during the bead washes (Fig. 3G inset), but
no detectible Aβwas lost in these washes (Fig. 3H,I insets). These results confirmed that dual antibody immunoprecipitation with ammonium hydroxide elution was an effective method for separating Aβfrom other proteins.

Quantitative bookkeeping.

We took aliquots from each step during our final purification protocol and
measured soluble Aβaggregate concentrations and total protein concentrations for the purposes of quantitative
bookkeeping. We found that a typical purification protocol resulted in over 6000 fold purification of soluble Aβ
aggregates relative to total protein and >60% recovery of the soluble Aβaggregates present in the original brain
lysate (Fig. 5). The recovery rate was calculated by measuring the concentration of soluble Aβaggregates in the
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Figure 7. Quick-freeze deep etch negative replica immunoelectron microscopic images of soluble Aβ
aggregates from human AD brain. (A,B) Exemplar images of soluble high molecular weight Aβ aggregates
immunoprecipitated from the sucrose cushion after 475,000× g ultracentrifugation spotted onto glass and
stained with N-terminal Aβantibody HJ3.4 followed by anti-mouse secondary conjugated to 6 nm diameter
gold beads. Replicas were produced by platinum deposition and mounted for imaging. Red arrows indicate
aggregates with multiple gold bead (white) labeling. Scale bars 100 nm: (C) Images with no primary antibody
indicating absence of nonspecific binding of gold-labeled secondary antibody. (D,E) Expanded view of
aggregates from panels A and B with contrast inverted to make the gold bead labels (black) more apparent.

initial lysates and the concentration in the final immunoprecipitated and eluted material from the 475,000×  g
sucrose cushion phase. The calculations were corrected for 5–10 microliter aliquots of material taken for analysis at each step of the purification. The small quantities of soluble Aβaggregates in the 100,000× g pellet and
in the 475,000× g supernatant were considered part of the ~40% loss. In 6 distinct preparations from 6 different
Alzheimer’s disease brain samples with extensive Aβplaque pathology (Supplementary Fig. 11), we recovered
approximately 2–6 ng dimer equivalents per gram of brain tissue and were able to enrich soluble Aβaggregates to
at least 0.1 to 0.6 percent of total protein (Supplementary Table 1). This enrichment may be a substantial underestimate; the actual purification may be substantially higher (see Discussion).

Morphological characteristics of soluble Aβ aggregates. We used immunoelectron microscopy (EM)

to directly characterize the size and number of Aβimmunoreactive sites per aggregate (Fig. 6). The N-terminal
specific antibody HJ3.4 was used for these analyses, followed by secondary antibodies conjugated to 6 nm gold
beads. The three differential ultracentrifugation separated fractions of Aβwere morphologically distinct. The
material immunoprecipitated from the low molecular weight (475,000× g supernatant) fraction consisted of
ovoid structures (Fig. 6A), on average ~200 nm in surface area (Fig. 6D), which bound typically exactly 1 but
occasionally 2 anti-Aβantibodies, (Fig. 6E). The material immunoprecipitated from the high molecular weight
soluble Aβaggregate (475,000× g sucrose cushion) fraction consisted of larger irregular structures (Fig. 6B), with
median size ~700 nm2 in surface area which bound typically 2-3 anti-Aβantibodies (range 1–9). The material
immunoprecipitated from the relatively insoluble high molecular weight (100,000× g pellet) fraction consisted of
even larger and more elongated structures (Fig. 6C), with median size 2000–29,000 nm2 in surface area and a wide
range of anti-Aβantibody binding stoichiometries. Some of the larger aggregates from the insoluble fraction had
irregular fibrillar mesh-like structures (Supplementary Fig. 12), whereas fibrillar structures were never observed
in the human brain soluble Aβaggregate fractions.
Quick-freeze deep etch immuno-EM further revealed that the soluble Aβaggregates consisted of clusters of
approximately 10 ×20 nm ovoid substructures, with each ovoid substructure appearing to bind at most 1 anti-Aβ
antibody (Fig. 7 and Supplementary Fig. 12). Quick-freeze deep etch methods were useful for morphology but
not optimal for automated quantitative analysis because the intensity of the edges was often similar to the intensity of the gold beads.
There were modest but statistically significant correlations between the area of the soluble high molecular
weight Aβaggregates and the number of anti-Aβantibodies bound (Supplementary Fig. 13). Based on the scatter
plots of area vs. number of anti-Aβantibodies bound, there appeared to be two different classes of soluble Aβ
Scientific Reports | 6:38187 | DOI: 10.1038/srep38187
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Figure 8. Mass spectrometry of soluble Aβ aggregates from human AD brain. (A) Liquid chromatographytandem mass spectrometry (LC-MS/MS) spectrum for undigested, full-length Aβ1-40. Each peak represents an
ion fragmented from Aβ1-40, with peaks labeled ‘b’ representing N-terminal fragment ions and peaks labeled ‘y’
representing C-terminal fragment ions. The numbers indicate measured mass/charge ratio (m/z). The single
letter amino acid code across the top indicates the de novo sequence identified by mass spectrometry, which
matches the amyloid precursor protein sequence corresponding to Aβ1-40. The line breaks between amino acids
indicate a cleavage of the amide bond between two adjacent amino acids producing fragment ions. The lines
below each amino acid indicate a detected ‘b’ ion, and lines above indicate a detected ‘y’ ion. Inset: isotopic
envelope for the +5 charged, full-length Aβ1-40: the peaks are spaced 0.2 daltons apart at z =  +5 because the
naturally occurring isotopes (e.g. 13C and 15N) differ by 1 dalton. For the +5 ion, the observed m/z was 866.4351
(theoretical m/z = 866.4370), which was −2.1 parts per million (ppm) error from the theoretical mass of Aβ1-40.
(B) Spectrum for full length Aβ1-42. For the +5 ion, the observed m/z was 903.2623 (theoretical m/z =  903.2612),
which was 1.2 ppm error from the theoretical mass of Aβ1-42.

aggregates; those for which there was a very strong linear relationship between area and antibody binding stoichiometry with approximately 200 nm2 per antibody binding, and those for which the area exceeded that which
could be accounted for by antibody binding stoichiometry. In this second class, a large portion of the surfaces
of the soluble Aβaggregates were not immunoreactive with the HJ3.4 antibody. This could indicate additional
constituents other than HJ3.4 immunoreactive Aβ. The correlation between area of the relatively insoluble high
molecular weight aggregates and the number of anti-Aβantibodies bound was very tight (Supplementary Fig. 14),
as would be expected for a single class of aggregates. There was also a large portion of the surfaces of the relatively
insoluble aggregates that was not immunoreactive with the HJ3.4 antibody. Synthetic Aβ1-40 aggregates were more
densely labeled by HJ3.4, but still not completely saturated with gold particles (Supplementary Fig. 12).

Mass spectrometric analysis of soluble Aβ aggregates. We performed top-down tandem mass spectrometry on the soluble Aβaggregates isolated from human AD brain and detected full length (undigested) Aβ1-40
and Aβ1-42 (Fig. 8 and Supplementary Fig. 15). The mass spectrometry results were very clean, with clear peaks
within the isotopic envelope spaced every 0.2 daltons, indicating a +5 charge state. A very large number of fragmented ‘b’ ions and ‘y’ ions were detected, yielding a high degree of confidence in the identity of the sequences.
These results confirm that the soluble Aβaggregate preparations from human AD brain truly contain Aβ. Many
other forms of Aβwere also detected (see below.)

Discussion

In summary we have developed a method for reliably enriching soluble Aβaggregates from human brain tissue,
separating them from other forms of Aβ, and purifying them more than 6000 fold with less than 40% loss of starting material. These soluble Aβaggregates are believed to be play a critical role in neurodegeneration relating to
Scientific Reports | 6:38187 | DOI: 10.1038/srep38187
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dementia of the Alzheimer’s type, however they had not been previously isolated from human brain and purified
sufficiently for detailed analysis. Our isolation and partial purification was sufficient for immunoelectron microscopic characterization, which indicated that these soluble Aβaggregates appear to consist of clusters of ovoid,
non-fibrillar structures typically with 2–3 binding sites for antibodies binding amino-terminal Aβ.
We are in the early stages of fully characterizing the specific Aβproteoforms present in the soluble Aβ aggregates using top-down (undigested) tandem mass spectrometry. Absolute quantification of the abundance of various forms of Aβin the soluble Aβaggregates has not yet been performed, but is an important area of ongoing
investigation. A full characterization of the Aβproteoforms and possible associated proteins is beyond the scope
of this communication.

Relationship to Previous Studies.

The relationship between our findings and those of previous research
groups investigating soluble Aβaggregates in human AD brain is complex (please see Supplementary Table 2
and Supplementary Discussion), but may be explained largely by differences in experimental methods. Our
results are most similar to those of Noguchi et al., who reported high molecular weight globular assemblies of Aβ
from Alzheimer’s disease human brain after saline-based homogenization24. In contrast, other investigators have
reported smaller forms of soluble Aβ assemblies20,23, or assessed partially dissociated aggregates likely derived
from water insoluble plaques41. Many of the previously reported preparations have involved SDS PAGE to assess
the size forms, which can both break apart larger Aβassemblies and cause monomeric Aβto aggregate ex vivo42.
A highly cited previous report23 used size exclusion chromatography to assess the size of the soluble Aβ aggregates, but the running buffer was ammonium acetate pH 8.5 which can cause changes in assembly of protein
complexes43–47. We found that ammonium acetate pH 8.5 consistently changes the apparent size of soluble Aβ
aggregates (Supplementary Fig. 16), though another recent report using a different assay indicates that it may not
always do so35. Furthermore, detection of the putative Aβassemblies often involved antibodies which recognize
epitopes present in amyloid precursor protein as well as Aβ, such that assemblies of Aβcannot be distinguished
unambiguously from fragments of amyloid precursor protein. Thus, although several groups have reported characteristics of soluble human brain Aβaggregates that differ from those described here, we have demonstrated
through a careful series of control experiments that our method minimizes many previously concerning potential
sources of ex vivo aggregation and de-aggregation.

Limitations and Future Directions.

The concentrations of soluble Aβaggregates measured here may be
underestimates, since our ELISA detects only species with at least 2 free canonical AβN-termini (amino acids
DAEFR…). Our initial data from mass spectrometric analysis indicate multiple other forms of Aβwith truncated
and post-translationally modified N-termini48. It is therefore likely that our enrichment of Aβmay be quantitatively greater than reported. For the same reason, the number of Aβpeptides per aggregate may also be underestimates. Future additional immunoelectron microscopy studies using antibodies recognizing different Aβ species
will be of interest.
Because the antibody HJ3.4 could also in theory recognize the C99 peptide or C-terminally truncated versions of this peptide, we cannot be absolutely certain that all of the detected particles represent Aβ. Our mass
spectrometry results, however, have not yet revealed any peptides longer than 43 amino acids (Wildburger et al.,
in preparation).
It is likely that there are other proteins associated with the soluble Aβaggregates characterized here; future
investigations involving discovery based mass-spectrometry and double immunoelectron microscopy validation
are underway, but are beyond the scope of this report.
We cannot be certain that the sizes of the aggregates and numbers of Aβbinding sites per aggregates represent
the state of these species in the living human brain. It is possible that post-mortem events such as autolysis could
have altered these aggregates. Experiments are underway to assess the effects of varying simulated post-mortem
intervals in transgenic mice. Methods to assess soluble Aβaggregates in the living human brain are still under
development. The relationship between soluble Aβaggregates in the brain and in the cerebrospinal fluid is likely
to be complex. To date, we and others have not been able to detect soluble Aβaggregates in human cerebrospinal
fluid40,49, though some groups have done so50–52. Assessments of brain biopsy tissue from patients undergoing
normal pressure hydrocephalus surgery, nearly half of whom may also have Aβ pathology53, represent a logical
direction for addressing potential post-mortem artifacts. Direct detection in the brain using molecularly specific
electrode technology may represent a novel approach54.
We also cannot be certain of whether changes in the properties of the soluble Aβaggregates occurred during
purification. The consistent size profile of the aggregates from raw lysates to finale eluates following immunoprecipitation indicate that there were no gross changes, but more subtle effects such as loss of low molecular weight
components cannot be ruled out. Likewise, the addition of exogenous monomeric Aβas a control for artifactual
aggregation would not be expected to mimic effects on intracellular Aβ. Selective binding to EM grids could also
have biased our observations. We cannot fully exclude a shift in apparent size of soluble Aβaggregates due to
interaction with the matrix during SEC. However, synthetic Aβmonomer and synthetic Aβdimer run true to size
under identical SEC conditions40. Furthermore, the large size observed by SEC is generally concordant with the
immuno-EM observations, though at present it is not possible to directly estimate the molecular weight of the
soluble Aβaggregates from the EM observations. A future direction will involve orthogonal biophysical characterization of the aggregates from raw lysates vs. final eluates based on charge (ion exchange) and hydrophobicity
(HIC). The quantities of soluble Aβaggregates we have extracted are as yet too low to allow dynamic light scattering, circular dichroism, or fast photochemical oxidation of protein- mass spectrometry.
The Aβspecies described here may be just one of many classes of soluble Aβaggregates. Other classes of
aggregates that do not bind HJ3.4 would not be detected or characterized. Thus, a priority for future research will
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be a broader exploration of the spectrum of Aβaggregates present in the human AD brain using other detection
reagents (see Supplementary Discussion).
Importantly, the physiological effects of the soluble Aβaggregates isolated and partially purified using these
methods has not been characterized. In previous studies, low molecular weight soluble Aβaggregates derived
from human brain potently impaired synaptic plasticity in rodent brain slices23 and caused tau hyperphosphorylation with morphological disruption in cultured neurons27. However, it was reported that the high molecular
weight soluble Aβaggregates after size exclusion chromatography in ammonium acetate did not affect synaptic
plasticity23. High molecular weight human brain aggregates separated in saline have been reported to cause toxicity in cultured neurons24. The relationship between these relatively acute in vitro physiological effects and slowly
progressive dementia of the Alzheimer’s type has yet to be determined. Underscoring the relevance of this line
of investigation is the finding that the levels of soluble Aβaggregates in lysates from human brain were strongly
related to dementia status, and fully differentiated demented from non-demented individuals after normalizing
for Aβplaque burden40.

Implications.

We anticipate that the method presented here for extracting, isolating, and purifying soluble
Aβaggregates will facilitate many additional investigations of the properties of these aggregates. One of the major
long-term goals of this line of investigation is to discover the distinguishing structural characteristics of the most
relevant forms of soluble Aβaggregates from the human brain. The specific details of their molecular composition will be of great interest with regard to developing specific candidate therapeutics to prevent their formation, enhance their clearance, or block their effects. Direct measurements of these soluble Aβaggregates in living
humans using biofluids or by molecular imaging could then be used for pharmacodynamic characterization of
candidate therapeutics. Importantly, the extent to which the soluble Aβaggregates present in the human brain is
similar to or different from the aggregates present in animal models of AD-like pathology is entirely unknown, but
critical for the field of therapeutic development. If one or more animal models faithfully recapitulates the soluble
Aβaggregates present in humans, it would seem logical to use these models for therapeutic development rather
than other models that do not accurately recapitulate the human-like aggregates. Thus, characterizing a range of
animal models of AD-like pathology is a top priority. It is possible, however, that none of the existing animal models accurately recapitulate human soluble Aβaggregates, and that new model systems will need to be developed55.
Furthermore, the purification scheme developed here may be thought of as a generalizable framework for
assessment of proteins aggregates relevant to human neurodegenerative diseases. Soluble aggregates of tau, alpha
synuclein, prion protein, TAR DNA-binding protein 43 (TDP43), fused in sarcoma (FUS), superoxide dismutase
1, huntintin, and others have been implicated in mediation of neurotoxic effects56 and are therefore potentially
relevant therapeutic targets but have not been characterized in human brain tissue.

Materials and Methods
Regulatory Compliance.

All protocols were carried out in accordance with the Charles F. and Joanne
Knight Alzheimer’s Disease Research Center and Washington University guidelines. This specific study was
approved by the Knight Alzheimer’s Disease Research Center tissue committee. All donors or their surrogates
gave informed consent for their brains to be used for research studies.

Homogenization of human cortical tissue.

Human frontal cortical tissue samples were obtained from
the Knight Alzheimer’s Disease Research Center at Washington University School of Medicine in Saint Louis,
Missouri. Cognitive status was determined with a validated retrospective postmortem interview with an informant to establish the Clinical Dementia Rating (CDR). Pathologically confirmed CDR3 cases were selected (n =  6,
84.1+/−6.6 years at death, 11.4+/−4.8 hours post mortem interval, 4 female & 2 male). In addition, two cognitively normal (CDR0, negative AD pathology) cases were selected for use in control experiments (n =  2). Frozen
cortical samples were weighed and placed into ice-cold Phosphate-Buffered Saline (PBS) containing protease
inhibitors (137 mM sodium chloride, 7.76 mM sodium phosphate dibasic, 2.17 mM monopotassium phosphate,
2.7 mM potassium chloride, 2 μg/mL aprotinin, 1 μg/mL leupeptin) followed by removal of leptomeninges and
apparent vasculature. The tissue was then immediately dounce homogenized in ice-cold PBS containing protease inhibitors at a 10:1 PBS volume:tissue weight ratio using a Potter-Elvehjem Teflon coated tissue grinder at
a constant 25 manual strokes. The addition of 3-[(3-Cholamidopropyl)dimethylammonio]-1-Propanesulfonate
(CHAPS) at a final concentration of 0.45% (w/v) was performed for experiments as detailed below.

Measurement of soluble Aβ aggregates. We adapted our previously developed40 “dimer equivalents”
ELISA assay to a 96-well format for the quantitation of soluble Aβaggregates during purification. The mouse
monoclonal antibody HJ3.4 was coated to 96-well Nunc Maxisorp plates (#464718, Nalge Nunc, Rochester, NY)
at 20 μg/mL in carbonate buffer (35 mM sodium bicarbonate, 16 mM sodium carbonate, 3 mM sodium azide,
pH 9.6) in 100 μl/well overnight at 4 °C. Plates were washed 5x between steps with PBS using a BioTek EXL405
plate washer (BioTek, Winooski, VT). The assay plates were blocked using 0.2 μm filtered 4% BSA (#7030,
Sigma-Aldrich, St. Louis, MO) in PBS for 1 hour at room temperature. Samples or dimer standard were added
neat or diluted in standard diluent (0.2 μm filtered 0.25% BSA, 0.005% Tween-20, 300 mM Tris, 3 mM sodium
azide, 2 μg/mL aprotinin, 1 μg/mL leupeptin, in PBS) to 100 μL final volume and loaded. An 8-point standard
curve was generated using 2000, 1000, 500, 250, 125, 62.5, and 31.25 pg/mL of Aβ1-40Ser26Cys dimer in DMSO
(AnaSpec, Fremont, CA) diluted in standard diluent and loaded in triplicate in all experiments. All samples and
standard were kept on ice during handling. Assay plates were incubated at 4 °C overnight. Biotinylated HJ3.4
at 100 ng/mL was then added in PBS containing 0.2 μm filtered 0.5% BSA plus 0.005% Tween-20 for 1 hour at
room temperature with gentle agitation. Poly-streptavidin HRP-20 (65R-S103PHRP, Fitzgerald, Acton, MA)
was then incubated at 30 ng/mL in PBS containing 0.2 μm filtered 0.5% BSA plus 0.005% Tween-20 for 1 hour
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at room temperature with gentle agitation. After a final wash, the assay was developed by addition of 3,3′,5,5′
-Tetramethylbenzidine (T5569, Sigma-Aldrich) and the absorbance was read on a BioTek Synergy 2 plate reader
at 650 nm.

Measurement of Aβ1−x isoforms.

Assessment of isoforms of Aβstarting with amino acid 1 and ending
after the mid-domain epitope of the capture antibody (approximately amino acid 28), here termed Aβ1−x, in the
purification steps was determined by ELISA using the mid-domain HJ5.1 to capture and the N-terminal specific
HJ3.4 to detect bound peptide. HJ5.1 was coated to 96-well Nunc Maxisorp plates at 20 μg/mL in carbonate buffer
(35 mM sodium bicarbonate, 16 mM sodium carbonate, 3 mM sodium azide, pH 9.6) in 100 μ/well overnight at
4 °C. Plates were washed 5x between steps with PBS using a BioTek EXL405 plate washer. The assay plates were
blocked using 0.2 μm filtered 4% BSA in PBS for 1 hour at room temperature. Samples and standard were diluted
in standard diluent (0.2 μm filtered 0.25% BSA, 0.5 M guanidine-HCl, 0.005% Tween-20, 300 mM Tris, 3 mM
sodium azide, 2 μg/mL aprotinin, 1 μg/mL leupeptin, in PBS) to a 100 μL volume and loaded. An 8-point standard
curve was generated using 2000, 1000, 500, 250, 125, 62.5, and 31.25 pg/mL of Aβ1-40 synthetic monomer peptide
(AnaSpec) and loaded in triplicate in all experiments. All samples and standard were kept on ice during handling.
Assay plates were incubated at 4 °C overnight. Development of the assay was identical to the soluble Aβ aggregate
assay as described above.

Assessment of other detergents for extraction of soluble Aβ aggregates. To determine the poten-

tial utility of common biochemical detergents for increased Aβrecovery we homogenized tissue in the presence of
sub-critical micelle concentration detergent in PBS with protease inhibitor. The following concentrations of each
detergent were used: sodium dodecyl sulfate (0.2% w/v), Triton X100 (0.018% v/v), Tween 20 (0.007% v/v),
6-O-(N-Heptylcarbamoyl)-methyl-α-D-glucopyranoside (Hecameg, 0.6% w/v), n-Octyl glucoside (0.55% w/v),
CHAPS (0.45% w/v). For each tissue sample, the material was finely diced prior to homogenization to ensure each
detergent received approximately similar quantities of input. Following centrifugation at 100,000× g RCF, the
homogenates were diluted and the amount of soluble Aβaggregate determined by ELISA.

™

®

Size exclusion chromatography. Analysis of the apparent molecular weight of the Aβaggregates was
achieved using size exclusion chromatography, which unlike most gel electrophoresis methods, does not require
SDS or similar detergents. A maximum of 1 mL of enriched aggregate was injected onto a Superdex 200 10/300
GL column attached to an AKTA Purifier FPLC (GE Healthcare) and eluted with PBS containing 0.2 μm filtered
0.05% BSA at a flow rate of 0.5 mL/min. A total of twenty-three 1 mL elution fractions were collected starting
from the 6th mL. The eluted volume was collected in 0.2 μm filtered 1% BSA blocked low-binding microcentrifuge tubes prior to further purification or analysis. Under identical conditions, we ran globular protein size standards (Biorad) included thyroglobulin (670 kDa), gamma-globulin (158 kDa), ovalbumin (44 kDa), myoglobin
(17 kDa), and vitamin B12 (1.35 kDa).
Controls for ex vivo Aβ aggregation during CHAPS homogenization.

To determine whether the
addition of CHAPS to the purification method induces ex vivo aggregation, CDR3 derived monomer was spiked
into cognitively normal human tissue during homogenization containing CHAPS at or below the critical micelle
concentration. In addition, synthetic Aβ1-42 was similarly spiked into cognitively normal human tissue during
homogenization containing CHAPS at 0.45% v/w in PBS. The homogenate was immediately centrifuged at
100,000× g RCF for 1 hour and the resulting supernatant applied to the soluble Aβaggregate ELISA to measure
the presence of any aggregates formed ex vivo. Furthermore, a 1 gram sample of cognitively normal cortex was
homogenized with 0.45% CHAPS-PBS spiked with 2 ng/mL AD derived monomer. The homogenate was processed using the differential centrifugation protocol as described above. The resulting concentrate was separated
by size exclusion chromatography on the Superdex 200 10/300 GL column and the presence or absence of soluble
Aβaggregates was assessed in the collected fractions.

Control for ex vivo Aβ aggregation in other detergents. To determine if the typical concentrations
of Triton X-100 (0.1–1.0%), sodium dodecyl sulfate (0.1–2.0%), and Tween20 (0.1–1.0%) results in ex vivo aggregation, we spiked 2 ng of AD-derived Aβmonomer at 2 ng/mL into homogenization buffer with the appropriate
amount of cortical tissue from a cognitively normal, AD pathology negative brain. Following homogenization
and centrifugation at 100,000× g RCF, the supernatant was loaded onto the soluble Aβaggregate ELISA and
developed as described.
Reducing Aβ loss by blocking with bovine serum albumin.

Non-specific loss of Aβduring multiple
procedural steps is an additive problem. A significant reduction in nonspecific loss was achieved by incubation
of every sample tube and micropipette tips with a solution of 0.2 μm filtered 1% BSA in PBS. Excess BSA was
removed by washing with molecular grade water and then the plasticware was dried prior to use. In addition,
during size exclusion chromatography we utilized 0.2 μm filtered 0.05% BSA in the mobile phase to reducing
nonspecific loss to the Superdex 200 chromatography resin.

Concentration by Macrosep concentrator. High molecular weight Aβaggregates were concentrated
using a 100 kDa molecular weight cut off centrifugal concentrator (#MAP100C36, Pall Corporation, Port
Washington, NY). Freshly prepared cortical homogenate was clarified at 100,000× g RCF and transferred to a
chilled 100 kDa molecular weight cut off concentrator. The concentrator was centrifuged at 4000× g RCF at 4 °C
until the sample was concentrated approximately 10-fold. The concentrations of soluble Aβaggregates were determined by ELISA.
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Ammonium sulfate precipitation. Owing to the high molecular weight nature of soluble Aβ aggregates
they can be readily precipitated by addition of ammonium sulfate. Over a period of 30 minutes an ice-cold saturated solution of ammonium sulfate was added to the 100,000× g spun homogenate to a final concentration
of 35% and then incubated on wet ice with gentle mixing for an additional 30 minutes. The precipitation was
transferred to a series of 30 mL polypropylene centrifuge tubes and spun at 30,000× g for 30 minutes in a Sorvall
RC5B Plus centrifuge using a SS-34 rotor operated at 4 °C. The resulting pellet was gently dissolved in ice-cold
PBS containing protease inhibitors prior to further purification methods. To determine whether the process of
ammonium sulfate precipitation induces ex vivo aggregation we performed a spike recovery assessment. Briefly,
approximately 1 gram of cortical tissue from a cognitively normal participant was homogenized as described
above with the addition of 2 ng/mL AD derived monomer. The homogenate was precipitated as described above
and then separated by size exclusion chromatography before being assessed for Aβ1−x and soluble Aβ aggregates
by ELISA.
Differential ultracentrifugation for isolation of soluble Aβ aggregates from other forms of
Aβ. The cortical homogenates were transferred to chilled 30 mL polypropylene centrifuge tubes (#3119-0030,

Nalgene) and spun at 17,000× g for 30 minutes in a Sorvall RC5B Plus centrifuge using a SS-34 rotor at 4 °C. The
supernatant was transferred to 26.3 mL polycarbonate tubes (#355618, Beckman Coulter) and spun at 100,000×  g
for 1 hour in a Beckman Optima XPN-100 ultracentifuge using a type 70-Ti rotor operated at 4 °C under vacuum. The debris pellet from the 100,000× g spin was reserved for further analysis. The resulting 100,000×  g spin
supernatant was immediately transferred to a new 26.3 mL tube and underlayed with 1 mL of sterile 70% sucrose.
The centrifuge tube was spun at 475,000× g for 1 hour in the Beckman Optima XPN-100 with a brake setting of
“2” to reduce disturbance of the resulting protein layers. The supernatant was carefully removed in 5 mL layers
and then a final 2 mL layer containing the high-molecular weight soluble Aβconcentrate overlaying the sucrose
cushion was removed.

Ion Exchange Chromatography (IEX). The binding capacity and the elution resolution of Aβspecies were
assessed using anion exchange chromatography. Attached to the AKTA Purifier, 4.7 mL HiScreen strong anion (Q
FF, #17-5053-01, GE Healthcare) column was equilibrated with 10 mM Tris, pH 8.0 prior to sample injection. A
sample volume of 1 mL of cortical homogenate, diluted 1:5 with 10 mM Tris pH 8.0 (Buffer A) to reduce sodium
chloride concentration, was injected onto the column. Following sample flowthrough, a gradient was performed
with 10 mM Tris, pH 8.0, 3 M sodium chloride (Buffer B). Fractions were collected during the full gradient and
assessed for soluble Aβaggregates to measure the overall binding and elution.
Hydrophobicity Interaction Chromatography (HIC).

The binding capacity and the elution resolution
of Aβspecies were assessed using HIC. Attached to the AKTA Purifier, a 4.7 mL HiScreen Butyl FF (#17-1357-01,
GE) column was equilibrated with 10 mM Tris, pH 8.0, 3 M sodium chloride prior to sample injection. A sample
volume of 1 mL of cortical homogenate, diluted 1:5 with 10 mM Tris pH 8.0, 3 M sodium chloride (Buffer A) to
increase the sodium chloride concentration, was injected onto the column. Following sample flow through, a
gradient was performed with 10 mM Tris, pH 8.0 (Buffer B). Fractions were collected during the full gradient and
assessed for soluble Aβaggregates to measure the overall binding and elution.

Conjugation of monoclonal antibodies to cyanogen bromide (CNBr) sepharose. Immunoprecipitation

of Aβwas performed using a combination of the N-terminal specific monoclonal, HJ3.457, and a mid-domain specific
monoclonal, HJ5.158, conjugated to CNBr-Sepharose beads. Purified monoclonals were dialyzed against coupling
buffer (0.1 M sodium carbonate, 0.5 M sodium chloride, pH 8.3) and then spun at 17,000× g in a table top refrigerated
centrifuge to remove aggregated antibody complexes. One gram of activated CNBr-Sepharose was combined with
a 6 mg equal mixture of each of the monoclonal antibodies in coupling buffer and incubated for 2 hours with gentle
mixing. Unoccupied binding sites were blocked for 1 hour with 1 M ethanolamine, pH 8.0. The beads were rinsed with
three cycles of 0.1 M sodium acetate, 0.5 M sodium chloride, pH 4.0 and coupling buffer to remove residual uncoupled
protein. The beads were then washed and stored in PBS containing 0.02% sodium azide at 4 °C. All conjugation steps
were performed at room temperature.

Immunoprecipitation (IP) of Aβ.

Following isolation, Aβwas immunopurified by addition of 100 μl dual
antibody conjugated CNBr-Sepharose bead slurry per milliliter of concentrate in a preblocked microcentrifuge
tube. Immunoprecipitation was allowed to occur overnight with gentle rotation (4 rpm) at 4 °C. The beads were
isolated by centrifugation (2000× g, 2 min), and the supernatant was removed and saved for analysis. The beads
were washed 15 times with 1 mL ice-cold PBS and gentle rotation for 2 minutes per wash. For assessment of total
protein in each wash step the beads were washed with 0.1x PBS buffer, due to sodium chloride sensitivity with
the NanoOrange assay. Bound Aβwas eluted by three rounds of 100 μl of 150 mM ammonium hydroxide and
agitation for 5 minutes each. The elution volumes were pooled into a BSA blocked microcentrifuge tube and
neutralized with 30 μl 3 M Tris, pH 7.2. Aliquots of the elution were removed for quantification of total protein,
Aβ1−x, and soluble Aβaggregates. Aβeluates were stored at −80 °C or used immediately for electron microscopy.

Alternative IP elution conditions. IP was performed on a freshly prepared cortical homogenate clarified
at 100,000× g RCF as described above. The total IP bead volume was divided into four separate tubes and then
300 μL of either 5 M lithium chloride, 150 mM ammonium hydroxide pH 10.5, 200 mM glycine pH 2.7, or 1x
NuPAGE LDS buffer (#NP0008, Invitrogen) was added to the respective tube and allowed to incubate at room
temperature, or 95 °C for the LDS buffer, for 15 minutes. The resulting eluent was removed and immediately
run over the Superdex 200 10/300 column and fractions collected. The distribution of Aβfollowing elution was
assessed by indirect ELISA using the mid-domain specific mAb HJ5.1.
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Quantification of protein during purification steps. Total protein during each step of the purification procedure was quantitatively tracked by measurement with a colorimetric bicinchoninic acid (BCA) assay
(#23225, ThermoFisher Scientific) using a reference BSA as the standard. Appropriate dilutions for each sample
and the standard were combined with the assay reagent in a 96-well microplate and measured by absorbance at
562 nm on the BioTek plate reader. Because the protein levels were below the limit of sensitivity for BCA, total
protein quantification of the immunoprecipitation wash steps and the resulting eluate were measured using a
fluorescence-based NanoOrange assay (#N6666, Thermofisher Scientific) using a reference BSA as the standard.
The lower limit of quantification for the NanoOrange assay is 150 ng/mL. Appropriate dilutions for each sample
and the standard were combined with the assay reagent in a 96-well microplate and measured by fluorescence by
excitation at 485 nm and emission at 590 nm on the BioTek plate reader. The NanoOrange assay produces interpretable results at sodium chloride concentrations of <30 mM.
Immunoelectron microscopy.

For quantification of purified amyloid aggregates, samples were absorbed
onto glow-discharged carbon-coated 200-mesh Formvar grids (FCF200-Cu-UA, Electron Microscopy Sciences)
by incubation of a 5 μL volume for two minutes. Sample grids were quenched for 30 minutes with quench buffer
(50 mM lysine, 50 mM glycine, 50 mM ammonium chloride) followed by blocking for 30 minutes with 1% bovine
serum albumin in NaHCa buffer (100 mM sodium chloride, 30 mM HEPES, 2 mM calcium chloride, pH 7).
Sample grids were then incubated with HJ3.4 (1 μg/mL) in blocking solution for 1 hour. Following three washes
with blocking solution, the grids were incubated with anti-mouse IgG conjugated to 6 nm colloidal gold (806.022,
Aurion) diluted 1:15 in blocking solution. The grids were washed three times with NaHCa buffer followed by
fixation in 2.5% glutaraldehyde for five minutes. The grids were negatively stained with a 1% (w/v) uranyl acetate
solution and allowed to dry prior to imaging. All labeling steps were performed at room temperature. Images
were collected using a JEOL JEM-1400 transmission electron microscope operating at 80 kV attached to an AMT
XR111 high-speed pixel phosphor-scintillated 12-bit CCD camera.
Qualitative imaging using quick-freeze deep etch electron microscopy was performed according to published
protocol, with minor modifications59. Samples were applied to acid cleaned glass chips and immunostained as
described as above. Coverslips were rinsed in dH2O and frozen by abrupt application of the sample against a liquid helium cooled copper block with a Cryopress freezing machine. Frozen samples were transferred to a liquid
nitrogen cooled Balzers 400 vacuum evaporator, etched for 20 minutes at −80 °C and rotary replicated with ~
2 nm platinum deposited from a 15° angle above the horizontal, followed by an immediate ~10 nm stabilization
film of pure carbon deposited from an 85° angle. Replicas were floated onto a dish of concentrated hydrofluoric
acid and transferred through several rinses of dH20 with a loopful of Photo-flo, picked up on formvar coated
grids, and imaged on the JEOL JEM-1400 transmission electron microscope.

FIJI based quantification of immunoelectron microscopy images.

For each sample, a series of ten
random 1282 × 957 nm fields containing gold-positive material was photographed on the JEOL JEM-1400 transmission electron microscope. Each image was subjected to local background subtraction followed by the creation of
separate threshold masks for the gold particles and the surrounding aggregates. The threshold settings were standardized across all samples to reduce selection bias. To quantify the surface area of each aggregate containing at least
1 gold particle, the Analyze Particles plugin in ImageJ60 was applied to an image stack containing both threshold
masks to generate gold particle positive aggregate regions of interest. To quantify the number of gold particles per
aggregate, the Analyze Particles plugin in ImageJ was again used with the same regions of interest but the (denser)
gold intensity threshold. The analysis was entirely automated, without user input after image selection.

Statistics. All data were analyzed in Prism 7.0 (GraphPad Software, La Jolla, CA). The Shapiro-Wilk normality test was used to determine whether the distribution of the Aβsurface area measurements and gold particle
counts were normally distributed. As the data sets displayed non-normal distributions in more than one group,
Kruskal-Wallis ANOVA with Dunn post hoc test was used to compare groups. Spearman r correlations were performed to assess the relationship between the Aβsurface area and the number of gold particles.
Ammonium acetate size exclusion chromatography.

To assess the size distribution of amyloid beta
aggregates using ammonium acetate during size exclusion chromatography, cortical tissue was homogenized
and centrifuged at 100,000× g RCF as described above. Each sample was injected onto a Superdex 200 10/300
column equilibrated with 50 mM ammonium acetate, pH 8.5 at 4 °C and fractions collected. Each sample was
subsequently injected on a Superdex 200 10/300 column equilibrated with 1x PBS at 4 °C and fractions collected.
The fractions were assessed using the Aβdimer equivalents ELISA.

Liquid chromatography tandem mass spectrometry.

Soluble Aβaggregates were eluted from IP with
100% formic acid and dried under vacuum. The samples were then precipitated with the 2D Clean-Up Kit (GE
Healthcare, Piscataway, NJ) to remove residual lipids, salt and polymers leached off of the beads used for immunoprecipitation during elution. The precipitated protein was resuspended in 100% formic acid. Samples were then
subjected to C8 cleanup (Glygen) to separate larger proteins from Aβpeptides. C8 eluant was dried to completeness
under vacuum and stored at −80 °C until analysis. Samples were resuspended in 1%/10%/5% formic acid/acetonitrile/methanol (v/v/v). The samples were analyzed by nanoLC-MS/MS on an Orbitrap Fusion mass spectrometer
(ThermoFisher) in positive ion mode. Chromatographic separation was performed on an ACQUITY UPLC HSS
T3 (360 μm OD ×  75 μm ID) column packed with 10 cm C18 (1.8 μm, 100 Å, Waters) at 300 nL/min and heated to
60 °C. MS files (.raw) were imported into PEAKS (version 7.5, Waters) and searched against a UniprotKB/SwissProt
Human database of canonical sequences (October 2015; 20,204 entries) appended with the cRAP contaminant
database (December 2015 version, The Global Proteome Machine, www.thegpm.org/cRAP/index.html).
Scientific Reports | 6:38187 | DOI: 10.1038/srep38187

13

www.nature.com/scientificreports/

References

1. Hardy, J. et al. Pathways to Alzheimer’s disease. Journal of internal medicine 275, 296–303, doi: 10.1111/joim.12192 (2014).
2. Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992).
3. Katzman, R. et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and
numerous neocortical plaques. Annals of neurology 23, 138–144 (1988).
4. Hulette, C. M. et al. Neuropathological and neuropsychological changes in “normal” aging: evidence for preclinical Alzheimer
disease in cognitively normal individuals. Journal of neuropathology and experimental neurology 57, 1168–1174 (1998).
5. Price, J. L. & Morris, J. C. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Annals of neurology 45,
358–368 (1999).
6. Aizenstein, H. J. et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of
neurology 65, 1509–1517 (2008).
7. Zolochevska, O. & Taglialatela, G. Non-Demented Individuals with Alzheimer’s Disease Neuropathology: Resistance to Cognitive
Decline May Reveal New Treatment Strategies. Current pharmaceutical design 22, 4063–4068 (2016).
8. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. The New England journal of
medicine 367, 795–804, doi: 10.1056/NEJMoa1202753 (2012).
9. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.
Proceedings of the National Academy of Sciences of the United States of America 95, 6448–6453 (1998).
10. Dahlgren, K. N. et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. The Journal of
biological chemistry 277, 32046–32053 (2002).
11. Wang, H. W. et al. Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat
dentate gyrus. Brain research 924, 133–140 (2002).
12. Townsend, M., Shankar, G. M., Mehta, T., Walsh, D. M. & Selkoe, D. J. Effects of secreted oligomers of amyloid beta-protein on
hippocampal synaptic plasticity: a potent role for trimers. The Journal of physiology 572, 477–492 (2006).
13. Selkoe, D. J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behavioural brain research 192,
106–113, doi: 10.1016/j.bbr.2008.02.016 (2008).
14. Ono, K., Condron, M. M. & Teplow, D. B. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proceedings of
the National Academy of Sciences of the United States of America 106, 14745–14750 (2009).
15. Nussbaum, J. M. et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 485, 651–655,
doi: 10.1038/nature11060 (2012).
16. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300,
486–489, doi: 10.1126/science.1079469 (2003).
17. Walsh, D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in
vivo. Nature 416, 535–539 (2002).
18. Cleary, J. P. et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8, 79–84
(2005).
19. Lesne, S. et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352–357 (2006).
20. Kuo, Y. M. et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. The Journal of biological
chemistry 271, 4077–4081. (1996).
21. McLean, C. A. et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Annals
of neurology 46, 860–866 (1999).
22. Barghorn, S. et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer’s
disease. Journal of neurochemistry 95, 834–847, doi: 10.1111/j.1471-4159.2005.03407.x (2005).
23. Shankar, G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory.
Nature medicine 14, 837–842 (2008).
24. Noguchi, A. et al. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from
Alzheimer disease brains. The Journal of biological chemistry 284, 32895–32905, doi: 10.1074/jbc.M109.000208 (2009).
25. Tomic, J. L., Pensalfini, A., Head, E. & Glabe, C. G. Soluble fibrillar oligomer levels are elevated in Alzheimer’s disease brain and
correlate with cognitive dysfunction. Neurobiology of disease 35, 352–358 (2009).
26. Pham, E. et al. Progressive accumulation of amyloid-beta oligomers in Alzheimer’s disease and in amyloid precursor protein
transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. The FEBS journal 277, 3051–3067,
doi: 10.1111/j.1742-4658.2010.07719.x (2010).
27. Jin, M. et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and
neuritic degeneration. Proceedings of the National Academy of Sciences of the United States of America 108, 5819–5824, doi: 10.1073/
pnas.1017033108 (2011).
28. Lesne, S. E. et al. Brain amyloid-beta oligomers in ageing and Alzheimer’s disease. Brain : a journal of neurology 136, 1383–1398,
doi: 10.1093/brain/awt062 (2013).
29. Gong, Y. et al. Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for
reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America 100, 10417–10422,
doi: 10.1073/pnas.1834302100 (2003).
30. Lasagna-Reeves, C. A., Glabe, C. G. & Kayed, R. Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain.
The Journal of biological chemistry 286, 22122–22130, doi: 10.1074/jbc.M111.236257 (2011).
31. Bjorklund, N. L. et al. Absence of amyloid beta oligomers at the postsynapse and regulated synaptic Zn2+in cognitively intact aged
individuals with Alzheimer’s disease neuropathology. Molecular neurodegeneration 7, 23, doi: 10.1186/1750-1326-7-23 (2012).
32. Upadhaya, A. R., Lungrin, I., Yamaguchi, H., Fandrich, M. & Thal, D. R. High-molecular weight Abeta oligomers and protofibrils are
the predominant Abeta species in the native soluble protein fraction of the AD brain. Journal of cellular and molecular medicine 16,
287–295, doi: 10.1111/j.1582-4934.2011.01306.x (2012).
33. Um, J. W. et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nature
neuroscience 15, 1227–1235, doi: 10.1038/nn.3178 (2012).
34. Dohler, F. et al. High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer’s disease.
Brain : a journal of neurology 137, 873–886, doi: 10.1093/brain/awt375 (2014).
35. Mc Donald, J. M. et al. The aqueous phase of Alzheimer’s disease brain contains assemblies built from approximately 4 and
approximately 7 kDa Abeta species. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 11, 1286–1305, doi: 10.1016/j.
jalz.2015.01.005 (2015).
36. Chimon, S. et al. Evidence of fibril-like beta-sheet structures in a neurotoxic amyloid intermediate of Alzheimer’s beta-amyloid.
Nature structural & molecular biology 14, 1157–1164, doi: 10.1038/nsmb1345 (2007).
37. Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nature
neuroscience 15, 349–357, doi: 10.1038/nn.3028 (2012).
38. Figueiredo, C. P. et al. Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not
the persistent impairment induced by low-molecular-weight oligomers. The Journal of neuroscience : the official journal of the Society
for Neuroscience 33, 9626–9634, doi: 10.1523/JNEUROSCI.0482-13.2013 (2013).

Scientific Reports | 6:38187 | DOI: 10.1038/srep38187

14

www.nature.com/scientificreports/
39. Suzuki, Y. et al. Resolution of oligomeric species during the aggregation of Abeta1-40 using (19)F NMR. Biochemistry 52,
1903–1912, doi: 10.1021/bi400027y (2013).
40. Esparza, T. J. et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Annals of neurology 73,
104–119, doi: 10.1002/ana.23748 (2013).
41. Roher, A. E. et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and
stability in Alzheimer’s disease. The Journal of biological chemistry 268, 3072–3083 (1993).
42. Pujol-Pina, R. et al. SDS-PAGE analysis of Abeta oligomers is disserving research into Alzheimer s disease: appealing for ESI-IMMS. Scientific reports 5, 14809, doi: 10.1038/srep14809 (2015).
43. Laganowsky, A., Reading, E., Hopper, J. T. & Robinson, C. V. Mass spectrometry of intact membrane protein complexes. Nature
protocols 8, 639–651, doi: 10.1038/nprot.2013.024 (2013).
44. Shi, X., Nishimura, Y., Akashi, S., Takamizawa, A. & Hiraoka, K. Evaluation of binding affinity of protein-mutant DNA complexes
in solution by laser spray mass spectrometry. Journal of the American Society for Mass Spectrometry 17, 611–620, doi: 10.1016/j.
jasms.2005.12.016 (2006).
45. Staeheli, V., Vallotton, M. B. & Burger, A. Detection of human anti-thyroxine and anti-triiodothyronine antibodies in different
thyroid conditions. The Journal of clinical endocrinology and metabolism 41, 669–675, doi: 10.1210/jcem-41-4-669 (1975).
46. Kapur, A., Beck, J. L., Brown, S. E., Dixon, N. E. & Sheil, M. M. Use of electrospray ionization mass spectrometry to study binding
interactions between a replication terminator protein and DNA. Protein science : a publication of the Protein Society 11, 147–157,
doi: 10.1110/ps.27702 (2002).
47. Akashi, S., Osawa, R. & Nishimura, Y. Evaluation of protein-DNA binding affinity by electrospray ionization mass spectrometry.
Journal of the American Society for Mass Spectrometry 16, 116–125, doi: 10.1016/j.jasms.2004.09.021 (2005).
48. Wildburger, N. C., Esparza, T. J., Cairns, N. J., Bateman, R. J. & Brody, D. L. In Alzheimer’s Association International Conference.
49. Yang, T. et al. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in
human brain but not CSF. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 9, 99–112, doi: 10.1016/j.
jalz.2012.11.005 (2013).
50. Fukumoto, H. et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. The
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 24, 2716–2726, doi: 10.1096/
fj.09-150359 (2010).
51. Klyubin, I. et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive
immunization. The Journal of neuroscience : the official journal of the Society for Neuroscience 28, 4231–4237 (2008).
52. Savage, M. J. et al. A sensitive abeta oligomer assay discriminates Alzheimer’s and aged control cerebrospinal fluid. The Journal of
neuroscience : the official journal of the Society for Neuroscience 34, 2884–2897, doi: 10.1523/JNEUROSCI.1675-13.2014 (2014).
53. Leinonen, V. et al. Cortical brain biopsy in long-term prognostication of 468 patients with possible normal pressure hydrocephalus.
Neuro-degenerative diseases 10, 166–169, doi: 10.1159/000335155 (2012).
54. Yuede, C. M. et al. Rapid in vivo measurement of beta-amyloid reveals biphasic clearance kinetics in an Alzheimer’s mouse model.
The Journal of experimental medicine 213, 677–685, doi: 10.1084/jem.20151428 (2016).
55. Kim, Y. H. et al. A 3D human neural cell culture system for modeling Alzheimer’s disease. Nature protocols 10, 985–1006,
doi: 10.1038/nprot.2015.065 (2015).
56. Eftekharzadeh, B., Hyman, B. T. & Wegmann, S. Structural studies on the mechanism of protein aggregation in age related
neurodegenerative diseases. Mechanisms of ageing and development 156, 1–13, doi: 10.1016/j.mad.2016.03.001 (2016).
57. Schwetye, K. E. et al. Traumatic brain injury reduces soluble extracellular amyloid-beta in mice: a methodologically novel combined
microdialysis-controlled cortical impact study. Neurobiology of disease 40, 555–564 (2010).
58. Kim, J. et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. The
Journal of neuroscience : the official journal of the Society for Neuroscience 31, 18007–18012, doi: 10.1523/JNEUROSCI.3773-11.2011
(2011).
59. Heuser, J. E. & Kirschner, M. W. Filament organization revealed in platinum replicas of freeze-dried cytoskeletons. J Cell Biol 86,
212–234 (1980).
60. Schindelin, J., Rueden, C. T., Hiner, M. C. & Eliceiri, K. W. The ImageJ ecosystem: An open platform for biomedical image analysis.
Mol Reprod Dev 82, 518–529, doi: 10.1002/mrd.22489 (2015).

Acknowledgements

We would like to thank the participants in the Knight ADRC who donated their brains for the study, Robyn
Roth for technical assistance with electron microscopy, David Holtzman and Hong Jiang for antibodies, Jacques
Benzinger for the generous gift of an FPLC, Tom Ellenberger for allowing us to use his ultracentrifuge, and
the Washington University Center for Cellular Imaging for access to the electron microscope. We gratefully
acknowledge helpful discussions with Jacques Benzinger, Gunnar Brinkmalm, John Cirrito, Ron Demattos, Tom
Ellenberger, Todd Golde, David Holtzman, Tom Kastan, Erik Portelius, Blaine Roberts, Tim Ryan, Dennis Selkoe,
Stephen Strittmatter, and Dominic Walsh. This work was supported by the BrightFocus Foundation A2014270S
(DLB), The Cure Alzheimer’s Fund 128873 (DLB), a Jeane B. Kempner Fellowship (NCW), the Charles F. and
Joanne Knight ADRC (NIH P50 AG05681, NIH P01 AG03991, NIH P01 AG026276) and NIH R01 NS065069
(DLB).

Author Contributions

T.J.E. and D.L.B. designed experiments, T.J.E., N.C.W., and H.J. performed experiments, T.J.E., and D.L.B.
performed primary data analysis. M.G. contributed novel analytical software, N.J.C. provided brain tissue and
pathological analyses, N.C.W. and D.L.B. obtained funding. R.J.B. provided mass spectrometry expertise and
equipment, T.J.E. and D.L.B. wrote the manuscript with intellectual contributions from all authors.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Esparza, T. J. et al. Soluble Amyloid-beta Aggregates from Human Alzheimer’s Disease
Brains. Sci. Rep. 6, 38187; doi: 10.1038/srep38187 (2016).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Scientific Reports | 6:38187 | DOI: 10.1038/srep38187

15

www.nature.com/scientificreports/
This work is licensed under a Creative Commons Attribution 4.0 International License. The images
or other third party material in this article are included in the article’s Creative Commons license,
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
© The Author(s) 2016

Scientific Reports | 6:38187 | DOI: 10.1038/srep38187

16

